 | Up a level |
Cohen, J. B., Engert, A., Ansell, S. M., Younes, A., Trneny, M., Savage, K. J., Ramchandren, R., Collins, G. P., Fanale, M. A., Armand, P., Zinzani, P. L., de Boer, J. P., Shipp, M. A., Santoro, A., Timmerman, J. M., Sacchi, M., Sy, O. and Kuruvilla, J. (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study. Br. J. Haematol., 181. S. 87 - 89. HOBOKEN: WILEY. ISSN 1365-2141
Engert, A., Domingo Domenech, E., Rueda, A., Armand, P., Trneny, M., Feldman, T., Ansell, S., Provencio, M., Jaeger, U., Cohen, J. B., Savage, K. J., Willenbacher, W., Sacchi, M., Sumbul, A. and Ramchandren, R. (2018). Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study. Oncol. Res. Treat., 41. S. 273 - 274. BASEL: KARGER. ISSN 2296-5262
Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J., Collins, G., Ramchandren, R., Cohen, J., De Boer, J. P., Kuruvilla, J., Savage, K., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL. Haematologica, 102. S. 145 - 146. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Engert, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., Cohen, J., Collins, G., Savage, K., Trneny, M., Kato, K., Farsaci, B., Parker, S., Rodig, S. and Younes, A. (2016). CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jaeger, U., Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncol. Res. Treat., 40. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262
Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY. Haematologica, 101. S. 44 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M. A., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zinzani, P. L., Engert, A., Younes, A., Santoro, A., Ansell, S., Timmerman, J., Collins, G., Armand, P., Savage, K. J., Trneny, M., Fanale, M., Kuruvilla, J., Cohen, J. B., Shipp, M., Rodig, S., Kato, K., Sumbul, A., Farsaci, B. A. and Ratanatharathorn, V. (2016). CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Haematologica, 101. S. 43 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078